Companies · Pharma

Medicus Pharma Ltd.

TORONTO · Pharma · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Medicus Pharma Ltd. — recommendation, valuation, rhythm, risks.
$15.9M
Total raised · real
2
Rounds
2.1×
Latest step-up
Top 26%
Sector rank · raised
Series A
Latest stage · inferred · Fri May 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Medicus Pharma Ltd. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.89× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era.
  • Within the normal band (89% of peer median) for its niche.
Quiet
  • Last raise 2.2 yr ago; this sector typically re-raises about every 16 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Medicus Pharma Ltd. is one of 310 Pharma companies tracked from TORONTO. By capital raised it ranks in the upper tier (ahead of 75% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
23
Investors (latest)
2024-05-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeries A · 2023-09-29 Raised $4.9M (real) Modeled valuation $36M (est)$4.9M$36MSeries A2023Series A · 2024-05-03 Raised $5.2M (real) Modeled valuation $29M (est)$5.2M$29MSeries A2024Series A · 2024-05-03 Raised $11M (real) Modeled valuation $61M (est)$11M$61MSeries A2024+$5.2M+$11MCumulative $21M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.9M · 2023
Series A extension$5.2M · 2024
Series A extension$11.0M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$61.0M
Base estimate est.
$12.6M
Conservative case
$136.8M
Upside case
$50.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $35.6M · 2023-09-292023Series A · modeled $28.6M · 2024-05-03Series A · modeled $61.0M · 2024-05-032024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
2.2 yr
Elapsed time used
2.2 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$26.8M/yr
Capital velocity
2.8 yr
On record since
2023
First round
3
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.5× above median
This company$15.9M
Sector median$6.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.6× above median
This company$11.0M
Sector median$6.7M
Modeled value — vs sector median (estimate, all stages) 1.0× of median
This company$61.0M
Sector median$62.5M

Raised more than 75% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #18 of 24.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Carmine Therapeutics, Inc. · Series A Raised $13.7M · modeled $161.9M (est)Triomics, Inc. · Series A Raised $13.8M · modeled $142.0M (est)Spiral Therapeutics Inc · Series A Raised $19.4M · modeled $120.5M (est)Convelo Therapeutics, Inc. · Series A Raised $12.8M · modeled $113.1M (est)ADvantage Therapeutics, Inc. · Series A Raised $19.0M · modeled $111.2M (est)Galaxy Therapeutics Inc. · Series A Raised $13.0M · modeled $91.9M (est)FireCyte Therapeutics, Inc. · Series A Raised $5.5M · modeled $85.4M (est)Cello Therapeutics, Inc. · Series A Raised $8.7M · modeled $85.0M (est)Grinta, Inc. · Series A Raised $9.5M · modeled $84.7M (est)Float Health Inc. · Series A Raised $10.0M · modeled $80.7M (est)Fuse Oncology, Inc. · Series A Raised $11.8M · modeled $79.4M (est)Spry Therapeutics Inc. · Series A Raised $15.0M · modeled $68.8M (est)Medicus Pharma Ltd. (this company) Raised $15.9M · modeled $61.0M (est)Medicus Pharma Ltd.
CompanyStageRaised · realValue · estvs peer med.
Carmine Therapeutics, Inc.Series A$13.7M$161.9M2.37×
Triomics, Inc.Series A$13.8M$142.0M2.08×
Spiral Therapeutics IncSeries A$19.4M$120.5M1.76×
Convelo Therapeutics, Inc.Series A$12.8M$113.1M1.66×
ADvantage Therapeutics, Inc.Series A$19.0M$111.2M1.63×
Galaxy Therapeutics Inc.Series A$13.0M$91.9M1.35×
FireCyte Therapeutics, Inc.Series A$5.5M$85.4M1.25×
Cello Therapeutics, Inc.Series A$8.7M$85.0M1.25×
Grinta, Inc.Series A$9.5M$84.7M1.24×
Float Health Inc.Series A$10.0M$80.7M1.18×
Fuse Oncology, Inc.Series A$11.8M$79.4M1.16×
Spry Therapeutics Inc.Series A$15.0M$68.8M1.01×
Medicus Pharma Ltd. this companySeries A$15.9M$61.0M0.89×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.9M2023-09-29$22.4M$35.6M90%
Series A$5.2M2024-05-03$23.5M$28.6M90%
Series A$11.0M2024-05-03$50.1M$61.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.9M2023-09-29
    • First recorded raise — entered as Series A.
    • 68 investors on this round.
  2. Series A$5.2M2024-05-03
    • Came back fast: 7 mo vs the ~16 mo sector norm.
    • Round roughly the size of the prior one.
    • 23 investors on this round.
  3. Series A$11.0M2024-05-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 23 investors on this round.
Intelligence
2024 ~Q3
Modeled next raise · ~4mo cadence
$23.5M
Modeled next size est.range $15.3M$37.5M
2.1×
Last step-up
$26.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Edward J. Brennan2 other2023-09
William L. Ashton2 other2023-09
Barry J. Fishman2023-09
Carolyn J. Bonner2023-09
Erica J. Monaco2024-05
Frank J. Lavelle2023-09
James J. Quinlan2023-09
Larry Kaiser2023-09
Raza J. Bokhari2023-09
Robert J. Ciaruffoli2023-09
Sara R. May2024-05
Registry & provenance

Medicus Pharma Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1997296
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
PanTher Therapeutics, Inc.PharmaSeries A$15.8M$11.4Msame sector · same stage
Endogena Therapeutics, Inc.PharmaSeries A$15.3M$124.4Msame sector · same stage
Oncology Health Partners, LlcPharmaSeries A$15.0M$62.5Msame sector · same stage
Spry Therapeutics Inc.PharmaSeries A$15.0M$68.8Msame sector · same stage
Civatech Oncology, Inc.PharmaSeries A$14.3M$133.3Msame sector · same stage
Qool Therapeutics, Inc.PharmaSeries A$14.2M$432.4Msame sector · same stage
Feel Therapeutics, Inc.PharmaSeries A$14.1M$229.9Msame sector · same stage
1200 Pharma LLCPharmaSeries A$14.1M$13.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Medicus One LLCOther Health CareSeed$27.4M84%
Gladius Therapeutics, Inc.PharmaPre-Seed$2.3M84%
Small Pharma Ltd.PharmaSeed$52.7M83%
Avisa Pharma Inc.PharmaSeed$17.5M83%
AR Pharma, Inc.PharmaPre-Seed$19.4M82%
Medicus Rx Holdings, LLCOther Health CarePre-Seed$12.3M82%
Modicus Prime Ltd.Other Health CareSeed$15.0M82%
EIP Pharma, Inc.PharmaSeries B$8.3M81%
Frequently asked
How much funding has Medicus Pharma Ltd. raised?
Medicus Pharma Ltd. has raised approximately $15.9M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Medicus Pharma Ltd.'s estimated valuation?
Provath's modeled valuation for Medicus Pharma Ltd. is approximately $61.0M (modeled range $12.6M–$136.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Medicus Pharma Ltd. at?
Medicus Pharma Ltd.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri May 03.
What does Medicus Pharma Ltd. do and where is it based?
Medicus Pharma Ltd. operates in the Pharma sector, based in TORONTO.
Explore related

See where Medicus Pharma Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Medicus Pharma Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.